Observational studyJournal of infusion nursing : the official publication of the Infusion Nurses Society
The Clinical and Economic Value of ClearGuard HD in the Inpatient Setting for Hemodialysis Catheter Management.
Observational study in Journal of infusion nursing : the official publication of the Infusion Nurses Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study was the first to assess inpatient use of ClearGuardTM HD antimicrobial barrier caps for the reduction of hemodialysis catheter-related central line-associated bloodstream infections (CLABSI) compared to the use of Tego™️ needlefree connectors with Curos™️ caps.
methodsRetrospective observational data were used to evaluate the effect of ClearGuard on the CLABSI rate and standardized infection ratio (SIR) compared to the baseline rate and ratio. Financial analysis was conducted to measure return on investment.
resultsCompared to the baseline period, data from the implementation period showed a long-term CLABSI reduction from 1.91/month/site (95% CI: [0.91-4.00]) to 0.71/month/site (95% CI: [0.33-1.53]), a 63% reduction (95% CI: [46%-74%]) in CLABSIs (P < .00005). The overall SIR was reduced by 57%, from a baseline of 0.721 to 0.310. The annual cost savings were estimated at $1.6 million.
conclusionThe findings from the ClearGuard study and ongoing use across hospitals indicate a clinically significant reduction in hemodialysis catheter-related CLABSI events and associated costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.